Drug intelligence / Profile preview

parconazole

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous, Intranasal

Overview

Parconazole is a broad-spectrum imidazole derivative with antifungal activity. It functions by inhibiting the cytochrome P450 dependent 14 alpha demethylation of lanosterol, a crucial step in the synthesis of ergosterol. Ergosterol is a vital component of fungal cell membranes. By disrupting ergosterol synthesis, parconazole compromises the integrity and permeability of the fungal cell membrane, leading to the loss of essential intracellular components and ultimately inhibiting fungal cell growth.

Other names: Parconazole [INN]68685-54-11-[[(2S,4R)-2-(2,4-dichlorophenyl)-4-(prop-2-ynoxymethyl)-1,3-dioxolan-2-yl]methyl]imidazoleEINECS 272-080-7EINECS272-080-7EINECS-272-080-7

Targets

CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on parconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on parconazole.

Explore the full profile